MDX060-05E: An open-label, phase II, extension study of MDX-060 [iratumumab] with gemcitabine in patients with relapsed or refractory Hodgkin's disease previously treated in protocol MDX060-05
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 23 Nov 2009
At a glance
- Drugs Iratumumab (Primary) ; Gemcitabine
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 23 Nov 2009 Actual initiation date (1 Mar 2007) and primary outcome added as reported by M.D. Anderson Cancer Center record.
- 23 Nov 2009 Status changed from not stated to active, no longer recruiting as reported by M.D. Anderson Cancer Center record.
- 23 Nov 2009 New source identified and integrated (M.D. Anderson Cancer Center, 2006-0122).